News of Note—Dynavax’s Heplisav-B, Emergent outlook and more

non
In this week's News of Note, Dynavax has launched its hepatitis B vaccine Heplisav-B in the U.S.

Here's some other vaccine news of note for the week:

> As GlaxoSmithKline and Merck & Co. face supply issues that have led to global hepatitis B vaccine shortage, Dynavax has launched its recently approved Heplisav-B in the U.S. at the wholesale acquisition price of $115 per dose, or $230 per regimen. Release

> Emergent BioSolutions announced its 2018 financial guidance. It expects full-year revenues of $715 million to $755 million, up from the just amended 2017 preliminary results of between $555 million and $560 million. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> The WHO prequalified the first typhoid conjugate vaccine, Typbar-TCV, manufactured by India’s Bharat Biotech, making the vaccine eligible for international procurement. The vaccine can be given to young children and has longer-lasting immunity than older versions. WHO Release

> A new study published in The Lancet found PharmaJet’s needle-free injection technology could augment Zika DNA vaccine immune responses. The Lancet study